Melatonin and delirium in the intensive care units: a systematic review and meta-analysis of randomized controlled trials
Lakbar I, et al.
Published in Intensive Care Medicine
Methodology
Systematic review and meta-analysis of randomized controlled trials of melatonin or melatonin receptor agonists in intensive care patients, with delirium incidence as the primary outcome and sleep, length of stay and mortality as secondary outcomes.
Key Findings
Pooling randomized trials in critically ill adults, melatonin or ramelteon did not significantly reduce delirium incidence, ICU length of stay or mortality compared with placebo.
Conclusions
Compared with placebo, melatonin does not reduce delirium incidence in critically ill patients.
Limitations
Heterogeneous delirium screening tools, differing doses and timing of melatonin, varied ICU case-mix, and several trials at moderate risk of bias.
Supplements Studied
Compared to placebo, melatonin does not reduce delirium incidence in critically ill patients.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.